ID   ATG7_HUMAN              Reviewed;         703 AA.
AC   O95352; B4E170; E9PB95; Q7L8L0; Q9BWP2; Q9UFH4;
DT   29-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   18-JUN-2025, entry version 199.
DE   RecName: Full=Ubiquitin-like modifier-activating enzyme ATG7 {ECO:0000305};
DE   AltName: Full=ATG12-activating enzyme E1 ATG7;
DE   AltName: Full=Autophagy-related protein 7;
DE            Short=APG7-like;
DE            Short=hAGP7;
DE   AltName: Full=Ubiquitin-activating enzyme E1-like protein;
GN   Name=ATG7 {ECO:0000312|HGNC:HGNC:16935}; Synonyms=APG7L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10233149; DOI=10.1091/mbc.10.5.1353;
RA   Yuan W., Stromhaug P.E., Dunn W.A. Jr.;
RT   "Glucose-induced autophagy of peroxisomes in Pichia pastoris requires a
RT   unique E1-like protein.";
RL   Mol. Biol. Cell 10:1353-1366(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 179-703 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   FUNCTION, SUBUNIT, AND INTERACTION WITH ATG12; GABARAP; GABARAPL2 AND
RP   MAP1LC3A.
RX   PubMed=11096062; DOI=10.1074/jbc.c000752200;
RA   Tanida I., Tanida-Miyake E., Ueno T., Kominami E.;
RT   "The human homolog of Saccharomyces cerevisiae Apg7p is a Protein-
RT   activating enzyme for multiple substrates including human Apg12p, GATE-16,
RT   GABARAP, and MAP-LC3.";
RL   J. Biol. Chem. 276:1701-1706(2001).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=11890701; DOI=10.1006/bbrc.2002.6645;
RA   Tanida I., Tanida-Miyake E., Nishitani T., Komatsu M., Yamazaki H.,
RA   Ueno T., Kominami E.;
RT   "Murine Apg12p has a substrate preference for murine Apg7p over three Apg8p
RT   homologs.";
RL   Biochem. Biophys. Res. Commun. 292:256-262(2002).
RN   [8]
RP   INTERACTION WITH ATG3 AND ATG12.
RC   TISSUE=Brain;
RX   PubMed=11825910; DOI=10.1074/jbc.m200385200;
RA   Tanida I., Tanida-Miyake E., Komatsu M., Ueno T., Kominami E.;
RT   "Human Apg3p/Aut1p homologue is an authentic E2 enzyme for multiple
RT   substrates, GATE-16, GABARAP, and MAP-LC3, and facilitates the conjugation
RT   of hApg12p to hApg5p.";
RL   J. Biol. Chem. 277:13739-13744(2002).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH GABARAP; GABARAPL2 AND MAP1LC3A.
RX   PubMed=16303767; DOI=10.1074/jbc.m505888200;
RA   Sou Y.S., Tanida I., Komatsu M., Ueno T., Kominami E.;
RT   "Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro
RT   target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16.";
RL   J. Biol. Chem. 281:3017-3024(2006).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   ACETYLATION, AND INTERACTION WITH EP300.
RX   PubMed=19124466; DOI=10.1074/jbc.m807135200;
RA   Lee I.H., Finkel T.;
RT   "Regulation of autophagy by the p300 acetyltransferase.";
RL   J. Biol. Chem. 284:6322-6328(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   INTERACTION WITH FOXO1.
RX   PubMed=20543840; DOI=10.1038/ncb2069;
RA   Zhao Y., Yang J., Liao W., Liu X., Zhang H., Wang S., Wang D., Feng J.,
RA   Yu L., Zhu W.G.;
RT   "Cytosolic FoxO1 is essential for the induction of autophagy and tumour
RT   suppressor activity.";
RL   Nat. Cell Biol. 12:665-675(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   FUNCTION, AND MUTAGENESIS OF PHE-15; ALA-16 AND PRO-17.
RX   PubMed=22170151; DOI=10.4161/auto.8.1.18339;
RA   Tanida I., Yamasaki M., Komatsu M., Ueno T.;
RT   "The FAP motif within human ATG7, an autophagy-related E1-like enzyme, is
RT   essential for the E2-substrate reaction of LC3 lipidation.";
RL   Autophagy 8:88-97(2012).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [18]
RP   INDUCTION.
RX   PubMed=23386620; DOI=10.1074/jbc.m112.422071;
RA   Desai S., Liu Z., Yao J., Patel N., Chen J., Wu Y., Ahn E.E., Fodstad O.,
RA   Tan M.;
RT   "Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through
RT   transcriptional regulation of autophagy-related protein 7 (ATG7).";
RL   J. Biol. Chem. 288:9165-9176(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-698, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   INTERACTION WITH ATG3, AND MUTAGENESIS OF TRP-243 AND ARG-246.
RX   PubMed=26043688; DOI=10.1016/j.bbrc.2015.05.107;
RA   Ohashi K., Otomo T.;
RT   "Identification and characterization of the linear region of ATG3 that
RT   interacts with ATG7 in higher eukaryotes.";
RL   Biochem. Biophys. Res. Commun. 463:447-452(2015).
RN   [21]
RP   UBIQUITINATION AT LYS-45, AND MUTAGENESIS OF LYS-45.
RX   PubMed=37943659; DOI=10.1016/j.celrep.2023.113402;
RA   Liu J., Lu S., Zheng L., Guo Q., Cao L., Xiao Y., Chen D., Zou Y., Liu X.,
RA   Deng C., Zhang S., Yang R., Wang Y., Zhang Y., Zhang N., Song X., Xing C.,
RA   Wang Z., Cao L.;
RT   "ATM-CHK2-TRIM32 axis regulates ATG7 ubiquitination to initiate autophagy
RT   under oxidative stress.";
RL   Cell Rep. 42:113402-113402(2023).
RN   [22]
RP   VARIANTS SCAR31 THR-234; ARG-261; ASP-511; PRO-512; HIS-576; MET-588;
RP   TYR-624 AND 659-ARG--ILE-703 DEL, INVOLVEMENT IN SCAR31, CHARACTERIZATION
RP   OF VARIANTS SCAR31 THR-234; ASP-511; HIS-576; MET-588 AND TYR-624,
RP   MUTAGENESIS OF CYS-572, AND FUNCTION.
RX   PubMed=34161705; DOI=10.1056/nejmoa1915722;
RA   Collier J.J., Guissart C., Olahova M., Sasorith S., Piron-Prunier F.,
RA   Suomi F., Zhang D., Martinez-Lopez N., Leboucq N., Bahr A.,
RA   Azzarello-Burri S., Reich S., Schoels L., Polvikoski T.M., Meyer P.,
RA   Larrieu L., Schaefer A.M., Alsaif H.S., Alyamani S., Zuchner S.,
RA   Barbosa I.A., Deshpande C., Pyle A., Rauch A., Synofzik M., Alkuraya F.S.,
RA   Rivier F., Ryten M., McFarland R., Delahodde A., McWilliams T.G.,
RA   Koenig M., Taylor R.W.;
RT   "Developmental Consequences of Defective ATG7-Mediated Autophagy in
RT   Humans.";
RL   N. Engl. J. Med. 384:2406-2417(2021).
CC   -!- FUNCTION: E1-like activating enzyme involved in the 2 ubiquitin-like
CC       systems required for cytoplasm to vacuole transport (Cvt) and
CC       autophagy. Activates ATG12 for its conjugation with ATG5 as well as the
CC       ATG8 family proteins for their conjugation with
CC       phosphatidylethanolamine. Both systems are needed for the ATG8
CC       association to Cvt vesicles and autophagosomes membranes. Required for
CC       autophagic death induced by caspase-8 inhibition. Facilitates LC3-I
CC       lipidation with phosphatidylethanolamine to form LC3-II which is found
CC       on autophagosomal membranes (PubMed:34161705). Required for mitophagy
CC       which contributes to regulate mitochondrial quantity and quality by
CC       eliminating the mitochondria to a basal level to fulfill cellular
CC       energy requirements and preventing excess ROS production. Modulates
CC       p53/TP53 activity to regulate cell cycle and survival during metabolic
CC       stress. Also plays a key role in the maintenance of axonal homeostasis,
CC       the prevention of axonal degeneration, the maintenance of hematopoietic
CC       stem cells, the formation of Paneth cell granules, as well as in
CC       adipose differentiation. Plays a role in regulating the liver clock and
CC       glucose metabolism by mediating the autophagic degradation of CRY1
CC       (clock repressor) in a time-dependent manner (By similarity).
CC       {ECO:0000250|UniProtKB:Q9D906, ECO:0000269|PubMed:11096062,
CC       ECO:0000269|PubMed:16303767, ECO:0000269|PubMed:22170151,
CC       ECO:0000269|PubMed:34161705}.
CC   -!- SUBUNIT: Homodimer (PubMed:11096062). Interacts with ATG3; this
CC       interaction is essential for the transfer of ATG8-like proteins's
CC       thioester from ATG7 to ATG3 and plays a role in the conjugation of
CC       ATG12 to ATG5 (PubMed:11825910, PubMed:26043688). Interacts with ATG12
CC       (PubMed:11096062, PubMed:11825910). Forms intermediate conjugates with
CC       GABARAPL1 (By similarity). Forms intermediate conjugates with ATG8-like
CC       proteins such as GABARAP, GABARAPL2 or MAP1LC3A (PubMed:11096062,
CC       PubMed:16303767). Interacts with EP300 acetyltransferase
CC       (PubMed:19124466). Interacts with FOXO1 (PubMed:20543840).
CC       {ECO:0000250|UniProtKB:Q9D906, ECO:0000269|PubMed:11096062,
CC       ECO:0000269|PubMed:11825910, ECO:0000269|PubMed:16303767,
CC       ECO:0000269|PubMed:19124466, ECO:0000269|PubMed:20543840,
CC       ECO:0000269|PubMed:26043688}.
CC   -!- INTERACTION:
CC       O95352; P29692: EEF1D; NbExp=2; IntAct=EBI-987834, EBI-358607;
CC       O95352; O95166: GABARAP; NbExp=8; IntAct=EBI-987834, EBI-712001;
CC       O95352; Q9H0R8: GABARAPL1; NbExp=6; IntAct=EBI-987834, EBI-746969;
CC       O95352; P60520: GABARAPL2; NbExp=8; IntAct=EBI-987834, EBI-720116;
CC       O95352; P14316: IRF2; NbExp=2; IntAct=EBI-987834, EBI-2866589;
CC       O95352; Q9GZQ8: MAP1LC3B; NbExp=7; IntAct=EBI-987834, EBI-373144;
CC       O95352; Q9UIY3: RWDD2A; NbExp=3; IntAct=EBI-987834, EBI-17677006;
CC       O95352; Q96EB6: SIRT1; NbExp=3; IntAct=EBI-987834, EBI-1802965;
CC       O95352-2; Q13148: TARDBP; NbExp=3; IntAct=EBI-15980880, EBI-372899;
CC       O95352-2; P04637: TP53; NbExp=4; IntAct=EBI-15980880, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Preautophagosomal
CC       structure {ECO:0000250}. Note=Also localizes to discrete punctae along
CC       the ciliary axoneme and to the base of the ciliary axoneme.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O95352-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O95352-2; Sequence=VSP_013205;
CC       Name=3;
CC         IsoId=O95352-3; Sequence=VSP_045206, VSP_045207;
CC   -!- TISSUE SPECIFICITY: Widely expressed, especially in kidney, liver,
CC       lymph nodes and bone marrow. {ECO:0000269|PubMed:11890701}.
CC   -!- INDUCTION: Expression is up-regulated by the transcription factor HSF1.
CC       {ECO:0000269|PubMed:23386620}.
CC   -!- DOMAIN: The C-terminal part of the protein is essential for the
CC       dimerization and interaction with ATG3 and ATG12. {ECO:0000250}.
CC   -!- DOMAIN: The N-terminal FAP motif (residues 15 to 17) is essential for
CC       the formation of the ATG89-PE and ATG5-ATG12 conjugates.
CC       {ECO:0000269|PubMed:22170151}.
CC   -!- PTM: Acetylated by EP300. {ECO:0000269|PubMed:19124466}.
CC   -!- PTM: Polyubiquitinated on Lys-45 via 'Lys-63'-linked ubiquitin by
CC       TRIM32; this modification positiely regulates ATG8 and ATG12 activating
CC       enzyme activity leading to initiation of autophagy under metabolic
CC       stress. {ECO:0000269|PubMed:37943659}.
CC   -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, 31 (SCAR31)
CC       [MIM:619422]: A form of spinocerebellar ataxia, a clinically and
CC       genetically heterogeneous group of cerebellar disorders due to
CC       degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCAR30 is characterized by global
CC       developmental delay, hypotonia, variably impaired intellectual and
CC       language development, ataxic gait, tremor, and dysarthria. Most
CC       affected individuals have optic atrophy. Additional features may
CC       include retinitis pigmentosa, sensorineural deafness, dysmorphic facial
CC       features, and possibly endocrine dysfunction.
CC       {ECO:0000269|PubMed:34161705}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the ATG7 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF094516; AAC69630.1; -; mRNA.
DR   EMBL; AK303694; BAG64682.1; -; mRNA.
DR   EMBL; AC020750; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022001; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC026185; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC083855; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000091; AAH00091.1; -; mRNA.
DR   EMBL; AL122075; CAB59250.1; -; mRNA.
DR   CCDS; CCDS2605.1; -. [O95352-1]
DR   CCDS; CCDS46752.1; -. [O95352-2]
DR   CCDS; CCDS46753.1; -. [O95352-3]
DR   PIR; T34556; T34556.
DR   RefSeq; NP_001129503.2; NM_001136031.3. [O95352-2]
DR   RefSeq; NP_001138384.1; NM_001144912.2. [O95352-3]
DR   RefSeq; NP_001336161.1; NM_001349232.2. [O95352-1]
DR   RefSeq; NP_001336162.1; NM_001349233.2. [O95352-1]
DR   RefSeq; NP_001336163.1; NM_001349234.2. [O95352-1]
DR   RefSeq; NP_001336164.1; NM_001349235.2. [O95352-1]
DR   RefSeq; NP_006386.1; NM_006395.3. [O95352-1]
DR   RefSeq; XP_011531584.1; XM_011533282.2.
DR   RefSeq; XP_011531588.1; XM_011533286.2.
DR   RefSeq; XP_016861033.1; XM_017005544.1.
DR   RefSeq; XP_016861034.1; XM_017005545.1.
DR   RefSeq; XP_016861035.1; XM_017005546.1.
DR   AlphaFoldDB; O95352; -.
DR   SMR; O95352; -.
DR   BioGRID; 115787; 421.
DR   DIP; DIP-29759N; -.
DR   FunCoup; O95352; 1882.
DR   IntAct; O95352; 138.
DR   STRING; 9606.ENSP00000346437; -.
DR   BindingDB; O95352; -.
DR   ChEMBL; CHEMBL2321621; -.
DR   TCDB; 9.A.15.2.1; the autophagy-related phagophore-formation transporter (apt) family.
DR   GlyGen; O95352; 1 site.
DR   iPTMnet; O95352; -.
DR   MetOSite; O95352; -.
DR   PhosphoSitePlus; O95352; -.
DR   SwissPalm; O95352; -.
DR   BioMuta; ATG7; -.
DR   jPOST; O95352; -.
DR   MassIVE; O95352; -.
DR   PaxDb; 9606-ENSP00000346437; -.
DR   PeptideAtlas; O95352; -.
DR   ProteomicsDB; 19175; -.
DR   ProteomicsDB; 50814; -. [O95352-1]
DR   ProteomicsDB; 50815; -. [O95352-2]
DR   Pumba; O95352; -.
DR   Antibodypedia; 1972; 818 antibodies from 46 providers.
DR   DNASU; 10533; -.
DR   Ensembl; ENST00000354449.7; ENSP00000346437.3; ENSG00000197548.13. [O95352-1]
DR   Ensembl; ENST00000354956.9; ENSP00000347042.5; ENSG00000197548.13. [O95352-2]
DR   Ensembl; ENST00000446450.6; ENSP00000412580.2; ENSG00000197548.13. [O95352-3]
DR   Ensembl; ENST00000685771.1; ENSP00000509725.1; ENSG00000197548.13. [O95352-1]
DR   Ensembl; ENST00000693202.1; ENSP00000510336.1; ENSG00000197548.13. [O95352-1]
DR   GeneID; 10533; -.
DR   KEGG; hsa:10533; -.
DR   MANE-Select; ENST00000693202.1; ENSP00000510336.1; NM_001349232.2; NP_001336161.1.
DR   UCSC; uc003bwc.4; human. [O95352-1]
DR   AGR; HGNC:16935; -.
DR   CTD; 10533; -.
DR   DisGeNET; 10533; -.
DR   GeneCards; ATG7; -.
DR   HGNC; HGNC:16935; ATG7.
DR   HPA; ENSG00000197548; Low tissue specificity.
DR   MalaCards; ATG7; -.
DR   MIM; 608760; gene.
DR   MIM; 619422; phenotype.
DR   OpenTargets; ENSG00000197548; -.
DR   VEuPathDB; HostDB:ENSG00000197548; -.
DR   eggNOG; KOG2337; Eukaryota.
DR   GeneTree; ENSGT00390000017509; -.
DR   HOGENOM; CLU_012998_1_0_1; -.
DR   InParanoid; O95352; -.
DR   OMA; RQIWDAI; -.
DR   OrthoDB; 338614at2759; -.
DR   PAN-GO; O95352; 11 GO annotations based on evolutionary models.
DR   PhylomeDB; O95352; -.
DR   PathwayCommons; O95352; -.
DR   Reactome; R-HSA-1632852; Macroautophagy.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; O95352; -.
DR   SIGNOR; O95352; -.
DR   BioGRID-ORCS; 10533; 31 hits in 1171 CRISPR screens.
DR   ChiTaRS; ATG7; human.
DR   GeneWiki; ATG7; -.
DR   GenomeRNAi; 10533; -.
DR   Pharos; O95352; Tchem.
DR   PRO; PR:O95352; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; O95352; protein.
DR   Bgee; ENSG00000197548; Expressed in monocyte and 152 other cell types or tissues.
DR   ExpressionAtlas; O95352; baseline and differential.
DR   GO; GO:0005930; C:axoneme; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0000407; C:phagophore assembly site; IDA:UniProt.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0019778; F:Atg12 activating enzyme activity; IDA:UniProt.
DR   GO; GO:0019779; F:Atg8 activating enzyme activity; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000045; P:autophagosome assembly; IMP:UniProt.
DR   GO; GO:0006914; P:autophagy; IMP:GO_Central.
DR   GO; GO:0071455; P:cellular response to hyperoxia; IDA:UniProtKB.
DR   GO; GO:0006995; P:cellular response to nitrogen starvation; IBA:GO_Central.
DR   GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB.
DR   GO; GO:0033554; P:cellular response to stress; IDA:UniProt.
DR   GO; GO:0051607; P:defense response to virus; IMP:CACAO.
DR   GO; GO:0016236; P:macroautophagy; IMP:BHF-UCL.
DR   GO; GO:0000423; P:mitophagy; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0034727; P:piecemeal microautophagy of the nucleus; IBA:GO_Central.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0031401; P:positive regulation of protein modification process; IDA:MGI.
DR   GO; GO:0006497; P:protein lipidation; IDA:MGI.
DR   GO; GO:0032446; P:protein modification by small protein conjugation; IBA:GO_Central.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   CDD; cd01486; Apg7; 1.
DR   FunFam; 3.40.140.100:FF:000001; Ubiquitin-like modifier-activating enzyme ATG7; 1.
DR   FunFam; 3.40.50.720:FF:000156; Ubiquitin-like modifier-activating enzyme ATG7; 1.
DR   FunFam; 3.40.140.70:FF:000001; Ubiquitin-like modifier-activating enzyme atg7; 1.
DR   Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1.
DR   Gene3D; 3.40.140.100; Ubiquitin-like modifier-activating enzyme ATG7 C-terminal domain; 1.
DR   Gene3D; 3.40.140.70; Ubiquitin-like modifier-activating enzyme ATG7 N-terminal domain; 1.
DR   InterPro; IPR006285; Atg7.
DR   InterPro; IPR032197; Atg7_N.
DR   InterPro; IPR042522; Atg7_N_1.
DR   InterPro; IPR042523; Atg7_N_2.
DR   InterPro; IPR045886; ThiF/MoeB/HesA.
DR   InterPro; IPR000594; ThiF_NAD_FAD-bd.
DR   InterPro; IPR035985; Ubiquitin-activating_enz.
DR   NCBIfam; TIGR01381; E1_like_apg7; 1.
DR   PANTHER; PTHR10953; UBIQUITIN-ACTIVATING ENZYME E1; 1.
DR   PANTHER; PTHR10953:SF3; UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME ATG7; 1.
DR   Pfam; PF16420; ATG7_N; 1.
DR   Pfam; PF00899; ThiF; 1.
DR   SUPFAM; SSF69572; Activating enzymes of the ubiquitin-like proteins; 1.
DR   neXtProt; NX_O95352; -.
DR   PharmGKB; PA134983397; -.
DR   TreeFam; TF105689; -.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Autophagy; Biological rhythms;
KW   Cytoplasm; Disease variant; Isopeptide bond; Neurodegeneration;
KW   Phosphoprotein; Protein transport; Proteomics identification;
KW   Reference proteome; Transport; Ubl conjugation; Ubl conjugation pathway.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895"
FT   CHAIN           2..703
FT                   /note="Ubiquitin-like modifier-activating enzyme ATG7"
FT                   /id="PRO_0000212806"
FT   MOTIF           15..17
FT                   /note="FAP motif"
FT   ACT_SITE        572
FT                   /note="Glycyl thioester intermediate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895"
FT   MOD_RES         698
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CROSSLNK        45
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:37943659"
FT   VAR_SEQ         138..176
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045206"
FT   VAR_SEQ         626..652
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_013205"
FT   VAR_SEQ         653..693
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045207"
FT   VARIANT         234
FT                   /note="P -> T (in SCAR31; results in decreased LC3-I
FT                   lipidation to form LC3-II)"
FT                   /evidence="ECO:0000269|PubMed:34161705"
FT                   /id="VAR_085979"
FT   VARIANT         261
FT                   /note="Q -> R (in SCAR31; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:34161705"
FT                   /id="VAR_085980"
FT   VARIANT         471
FT                   /note="V -> A (in dbSNP:rs36117895)"
FT                   /id="VAR_053014"
FT   VARIANT         511
FT                   /note="G -> D (in SCAR31; results in severely decreased
FT                   LC3-I lipidation to form LC3-II)"
FT                   /evidence="ECO:0000269|PubMed:34161705"
FT                   /id="VAR_085981"
FT   VARIANT         512
FT                   /note="L -> P (in SCAR31; in homozygous patient cells it
FT                   results in diminished autophagic flux)"
FT                   /evidence="ECO:0000269|PubMed:34161705"
FT                   /id="VAR_085982"
FT   VARIANT         576
FT                   /note="R -> H (in SCAR31; results in decreased LC3-I
FT                   lipidation to form LC3-II)"
FT                   /evidence="ECO:0000269|PubMed:34161705"
FT                   /id="VAR_085983"
FT   VARIANT         588
FT                   /note="V -> M (in SCAR31; results in severely decreased
FT                   LC3-I lipidation to form LC3-II)"
FT                   /evidence="ECO:0000269|PubMed:34161705"
FT                   /id="VAR_085984"
FT   VARIANT         624
FT                   /note="H -> Y (in SCAR31; results in decreased LC3-I
FT                   lipidation to form LC3-II)"
FT                   /evidence="ECO:0000269|PubMed:34161705"
FT                   /id="VAR_085985"
FT   VARIANT         659..703
FT                   /note="Missing (in SCAR31)"
FT                   /evidence="ECO:0000269|PubMed:34161705"
FT                   /id="VAR_085986"
FT   MUTAGEN         15
FT                   /note="F->D: Impairs conjugation activity; when associated
FT                   with D-16 and D-17."
FT                   /evidence="ECO:0000269|PubMed:22170151"
FT   MUTAGEN         16
FT                   /note="A->D: Impairs conjugation activity; when associated
FT                   with D-15 and D-17."
FT                   /evidence="ECO:0000269|PubMed:22170151"
FT   MUTAGEN         17
FT                   /note="P->D: Impairs conjugation activity; when associated
FT                   with D-15 and D-16."
FT                   /evidence="ECO:0000269|PubMed:22170151"
FT   MUTAGEN         45
FT                   /note="K->R: Impairs interaction with ATG12. Impairs
FT                   inrteraction with MAP1LC3B."
FT                   /evidence="ECO:0000269|PubMed:37943659"
FT   MUTAGEN         243
FT                   /note="W->A: Moderately impairs ATG3 binding. Moderately
FT                   reduces GABARAP-ATG3 thioester bond formation. Moderately
FT                   reduces GABARAP lipidation."
FT                   /evidence="ECO:0000269|PubMed:26043688"
FT   MUTAGEN         246
FT                   /note="R->D: Almost completely impairs ATG3 binding.
FT                   Severely reduces GABARAP-ATG3 thioester bond formation.
FT                   Severely reduces GABARAP lipidation."
FT                   /evidence="ECO:0000269|PubMed:26043688"
FT   MUTAGEN         572
FT                   /note="C->A: Loss of LC3-I lipidation to form LC3-II."
FT                   /evidence="ECO:0000269|PubMed:34161705"
FT   CONFLICT        210
FT                   /note="V -> A (in Ref. 2; BAG64682)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        346
FT                   /note="P -> L (in Ref. 2; BAG64682)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   703 AA;  77960 MW;  ABBD1A29A6C58356 CRC64;
     MAAATGDPGL SKLQFAPFSS ALDVGFWHEL TQKKLNEYRL DEAPKDIKGY YYNGDSAGLP
     ARLTLEFSAF DMSAPTPARC CPAIGTLYNT NTLESFKTAD KKLLLEQAAN EIWESIKSGT
     ALENPVLLNK FLLLTFADLK KYHFYYWFCY PALCLPESLP LIQGPVGLDQ RFSLKQIEAL
     ECAYDNLCQT EGVTALPYFL IKYDENMVLV SLLKHYSDFF QGQRTKITIG VYDPCNLAQY
     PGWPLRNFLV LAAHRWSSSF QSVEVVCFRD RTMQGARDVA HSIIFEVKLP EMAFSPDCPK
     AVGWEKNQKG GMGPRMVNLS ECMDPKRLAE SSVDLNLKLM CWRLVPTLDL DKVVSVKCLL
     LGAGTLGCNV ARTLMGWGVR HITFVDNAKI SYSNPVRQPL YEFEDCLGGG KPKALAAADR
     LQKIFPGVNA RGFNMSIPMP GHPVNFSSVT LEQARRDVEQ LEQLIESHDV VFLLMDTRES
     RWLPAVIAAS KRKLVINAAL GFDTFVVMRH GLKKPKQQGA GDLCPNHPVA SADLLGSSLF
     ANIPGYKLGC YFCNDVVAPG DSTRDRTLDQ QCTVSRPGLA VIAGALAVEL MVSVLQHPEG
     GYAIASSSDD RMNEPPTSLG LVPHQIRGFL SRFDNVLPVS LAFDKCTACS SKVLDQYERE
     GFNFLAKVFN SSHSFLEDLT GLTLLHQETQ AAEIWDMSDD ETI
//
